Mucormycosis in a Renal Transplant Recipient: Case Report and Comprehensive Review of Literature

Table 1

Success rate of antifungal agents used to treat mucormycosis.

Treatment	Study	Number of patients and patient population	Dosage	Success rate
ABLC	Singh et al. [6]^a	50, SOTs	NR	5/8 (62%)
	Forrest and Mankes [29]	6, KTs	5–10 mg/kg	3/6 (50%)
	Reed et al. [30]	41, ROM/ROCM; (2 KTs, 2 HSCTs)	5–10 mg/kg	7/22 (32%)
LAmB	Singh et al. [6]	50, SOTs	NR	16/17 (94%)
	Reed et al. [30]^b	41, ROM/ROCM; (2 KTs, 2 HSCTs)	5–10 mg/kg	13/19 (68%)
	Pagano et al. [31]	59, hematologic malignancy	3 mg/kg	7/12 (58%)
AmB deoxycholate	Singh et al. [6]	50, SOTs	NR	3/5 (60%)
	Reed et al. [30]^b	41, ROM/ROCM; (2 KTs, 2 HSCTs)	1 mg/kg	13/19 (68%)
	Pagano et al. [31]	59, hematologic malignancy	3 mg/kg	9/39 (23%)
Posaconazole monotherapy as second line	Van Burik et al. [32]	91, (10 SOTs)	800 mg daily	CR: 13/91 (14%); PR: 42/91 (46%)
	Greenberg et al. [33]	24, (4 SOTs)	800 mg daily	19/24 (79%)
Posaconazole monotherapy as first line	Peel et el. [34]	1, patient with SLE	800 mg daily	1/1 (100%)
	Singh et al. [6]	5, SOTs	NR	3/5 (60%)
LAmB and posaconazole	Singh et al. [6]	5, SOTs	NR	2/5 (40%)
	Rickerts et al. [35]	1, AML	5 mg/kg and 800 mg daily	1/1 (100%)
ABLC and caspofungin	Reed et al. [30]	41, ROM/ROCM; (2 KTs, 2 HSCTs)	5 mg/kg; NR	6/6 (100%) versus 14/31 (45%) for ABLC alone

ABLC: amphotericin B lipid complex; LAmB: liposomal AmB; AmB: amphotericin B; NR: not reported. ROCM: rhino-orbito-cerebral mucormycosis; SOT: solid organ transplant; KT: kidney transplant; HSCT: hematopoietic stem cell transplant. ^aThe only prospective study; ^bsuccess rate was combined for both treatment groups. CR: complete response; PR: partial response; AML: acute myeloid leukemia.